Research funder · United States
Michael J. Fox Foundation for Parkinson's Research
Non-profit organization in the USA
- Grants since 2016
- 1 275
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 3 085
- Funded works, all time
- 6 716
Grants
2025 · research · Fall 2025 RFP: Data Advice To Action - DATA-PD
Machine Leaning Based Proteomics Integration Reveals Biomarkers of Disease Pathology and Longitudinal Progression in PD and DLB
Saima Rathore · Emory University
2025 · research · Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology
Structural determination of PD-associated GCase variants in complex with LIMP-2
Friederike Zunke · Universitätsklinikum Erlangen, Department Of Molecular Neurology
2025 · research · Freezing of Gait Program
Treating Freezing of Gait in Parkinson’s Disease Using an ADHD Drug that Reduces Neural Cross-talk: A Multi-center Multi-modal Approach
Jorik Nonnekes · Radboud University Medical Center And Sint Maartenskliniek Nijmegen
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Late-preclinical Development of a Differentiated TRPML1 Agonist to Slow Progression of Parkinson’s Disease
Robert A. Craig · Tenvie Therapeutics
2025 · research · Research Grant
Clinical Development of 18F-RO7196581:A High-resolution PET Imaging Study Using NeuroExplorer
Gilles D. Tamagnan · Xingimaging, A Mitro Company
2025 · research · Spring 2025 RFA: Molecular MRI Biomarker Program
Novel Molecular Magnetic Resonance Imaging to Visualize and Quantify Impaired Brain Mitochondrial Bioenergetics in Parkinson's Disease
Wei Chen · University of Minnesota
2025 · research · Seed Amplification Assay Innovation Program
Quantitative SAAs for Alpha-synuclein from Various Matrices
Alexander Kai Buell · Technical University of Denmark
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Testing Biofluid Samples from the Arizona Study of Aging and Neurodegenerative Disorders for Alpha-synuclein and Biomarkers of Alzheimer’s Disease
Thomas Beach · Banner Sun Health Research Institute
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Douglas Galasko · University of California San Diego
2025 · research · Research Grant
First-in-human Evaluation of [11C]UCB-1A as Imaging Marker for Vesicle Glycoprotein 2C (SV2C): a PET Study in Healthy Volunteers and in Subjects with Parkinson’s Disease
Andrea Varrone · Karolinska Institutet
2025 · research · Research Grant
Discovery of Alpha-synuclein PET Tracer for Parkinson’s Disease
Sjoerd J. Finnema · Abbvie Inc.
2025 · research · Research Grant
FUN-MITO: Functional Validation of Mitochondrial Polygenic Risk Scores in the PPMI Cohort
Anne Grünewald · University of Luxembourg
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Developing Novel Lysosome-based Translational Biomarkers and Ion-Channel Agonists as Therapeutics for Parkinson’s Disease
Xiang Wang · Nico Therapeutics
2025 · research · Circuits & Cellular Targets for PD’s Symptoms
Role of B2*-Nicotinic Receptors in Parkinson’s Disease Related Circuits and Symptoms
Maxime Assous · Cardiff University
2025 · research · Research Grant
Identifying and Pilot Testing Best Practices for Sharing Amyloid PET Research Information with Individuals Living with Lewy Body Diseases
Melissa Armstrong · University of Florida
2025 · research · ASAP CRN Competitive Renewal Opportunity
Senescence in Parkinson’s Disease and Related Disorders
Michael Lee · University of Minnesota
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Laura Parkkinen · University of Oxford
2025 · research · Neuronal Synuclein Disease Endotypes 2024
BIOLOGY IS THE DISEASE: Identifying Biological Endophenotypes Based on Alpha-synuclein and AD Pathology Profiles and Evaluate NSD-ISS Stage 3-6
Kathrin Brockmann · Department Of Neurodegeneration, Hertie-institute For Clinical Brain Research
2025 · research · T2T Validation - NOD2
Investigating the Potential Role of NOD2 Activation in Reducing a-synuclein Aggregation and Toxicity in Human Cellular and Pre-clinical Models of Parkinson’s Disease
Abid Oueslati · Université Laval
2025 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Validating Hallmarks of Inflammation in a Preclinical Alpha-synuclein Model of Parkinson’s Disease
Jae-Kyung Lee · University of Georgia
2025 · research · Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology
RNAi Therapeutics Targeting Stearoyl-CoA-Desaturase as a Disease-modifying Treatment for Parkinson’s Disease
Saranna Fanning · Harvard University
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Neuroprotective Therapy for PD Using Stabilizers of the LRRK2:14-3-3 Interaction, Supplement
Jean-Marc Taymans · Umr-s1172, Jean-pierre Aubert Research Center (inserm - Lille University - Lille University Hospital
2025 · research · Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology
Determining PINK1 and PRKN Enzyme Activities In Vivo.
Kelly Lynn Stauch · University of Nebraska Medical Center
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Development of Anti-TLR2 Antibody Encapsulated with Polymer Nanoparticles Using a DNA Bar-coding Technology for Enhanced Brain Delivery
Seung-Jae Lee · The Parkinson's Institute
2025 · research · Research Grant
Identifying Protein Changes Associated with Parkinson’s Disease: Proteomics Public Data Compilation
Carlos Cruchaga · Washington University in St. Louis
2025 · research · T2T Validation - NOD2
Assessing the Role Played by NOD2 in Murine Models of PD
Stephen E. Girardin · University of Toronto
2025 · research · T2T Validation - NOD2
Development and Validation of Synthetic NOD2 Modulators for Parkinson’s Disease
Howard C. Hang · Scripps Research Institute
2025 · research · Seed Amplification Assay Innovation Program
Detection of Alpha-synuclein Aggregates in Tear Fluid of Patients with Parkinson’s Disease
Paul Lingor · Tum Klinikum Rechts Der Isar
2025 · research · T2T Validation - Endolysosomal Targets
In Vivo Efficacy of a TRPML1 Activating Compound in Alpha-synuclein PD Pre-clinical Models
Jacob Eriksen · Nine Square Therapeutics
2025 · research · Seed Amplification Assay Innovation Program
Quantitative SAA for Measuring Disease Progression in Parkinson’s Disease from Plasma
Vikram Khurana · Mass General Brigham
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Development of a Sequence Specific LRRK2-targeted Parkinson's Disease Splice Switching Oligonucleotide Drugs
Brage Storstein Andresen · Inverna Therapeutics
2025 · research · Spring 2025 RFA Seed Amplification Assay Innovation Program
Development of an Efficient Method to Capture Synuclein Seeds from Biological Samples for Detection Using SynSAA
Luis Concha · Amprion (United States)
2025 · research · Measuring Alpha-Synuclein in Extracellular Vesicles
Measurement of Alpha-synuclein in Plasma Extracellular Vesicles after Automated Isolation
David R. Walt · Brigham and Women's Hospital
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Development of CNS-Specific mTOR Inhibition for Enhanced Autophagy and Alpha-synuclein Clearance in Parkinson’s Disease
Nicholas T. Hertz · Montara Therapeutics, Inc.
2025 · research · MRI Biomarkers Program
Molecular MRI Correlates of Parkinsonian Neurodegeneration
Daniel E. Huddleston · Emory University
2025 · research · Research Grant
Brain Systems and Neurodegenerative Co-pathologies in Sleep Disturbance
Sharon Linda Naismith · The University of Sydney
2025 · research · Alpha-Synuclein Post-Translational Modifications Quantification Program
SUPPLEMENT: Spatially Resolved Proteomics for Quantitative Mapping of Post-Translational Modifications of Alpha-synuclein
Matthias Mann · Max Planck Institute of Biochemistry
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Next Generation Treg Therapy for Parkinson’s Disease
Howard E. Gendelman · University of Nebraska Medical Center
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
SUPPLEMENT: IRL757 for the Treatment of Apathy in Parkinson's Disease
Joakim Tedroff · Integrative Research Laboratories
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Novel Small Molecules to Slow PD Progression in a Genetically Defined Subset of People with PD
Warren D. Hirst · Dacapo Brainscience